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systemic lupus erythematosus.
Background. Adiponectin is an adipocyte-derived cytokine
that has anti-inflammatory properties. A preliminary pro-
teomic evaluation of urine for biomarkers of systemic lu-
pus erythematosus (SLE) nephritis demonstrated high levels
of adiponectin in SLE urine. This prompted investigation of
adiponectin expression in human SLE.
Methods. Adiponectin was measured by enzyme-linked im-
munosorbent assay (ELISA) in the urine and plasma of a clin-
ically well-characterized SLE cohort, with renal and nonrenal
SLE being followed in a prospective longitudinal study to iden-
tify risk factors for SLE flare. Renal adiponectin expression was
assessed by immunohistochemical analysis of kidney biopsies
from SLE nephritis patients.
Results. Cross-sectional testing showed that plasma
adiponectin levels were higher in patients with renal SLE
flare than normal controls or patients with nonrenal SLE
flare, after accounting for race and body mass index. Urine
adiponectin levels increased significantly with renal flare, but
not nonrenal SLE flare. Longitudinal testing revealed that
the urine adiponectin increase began in the 2 months prior to
renal flare. Urine adiponectin correlated with plasma levels
and magnitude of proteinuria, and to a lesser extent serum
creatinine. Plasma adiponectin levels were independent of
renal function and proteinuria. In kidney biopsies, adiponectin
was found on endothelial surfaces in normal and SLE kidneys,
and on podocytes and in the tubules of SLE kidneys.
Conclusion. Plasma adiponectin levels are increased in pa-
tients with renal SLE compared to healthy controls and pa-
tients with nonrenal SLE. During renal but not nonrenal
SLE flare, urine adiponectin levels increase significantly. Urine
adiponectin may be a biomarker of renal SLE flare.
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To better understand the risk factors for kidney
involvement in human systemic lupus erythematosus
(SLE), we have been engaged in biomarker discovery
in patients enrolled in the Ohio SLE Study (OSS), a
prospective longitudinal investigation of risk factors for
SLE flare in recurrently active patients with renal or
nonrenal SLE. One of the key goals of the study is to
identify biomarkers that distinguish renal from nonrenal
SLE activity. Such biomarkers could be useful to predict
impending renal flare or response to therapy, or iden-
tify novel mechanisms of kidney injury that may lead
to new therapies. Our approach to biomarker discov-
ery included analysis of urine samples with an immo-
bilized antibody array designed to reveal the presence
of cytokines in biologic fluids. Using this approach, we
found that one of the most highly expressed urinary pro-
teins was adiponectin. Adiponectin is emerging as an im-
portant immunomodulatory adipocyte-derived cytokine
(adipokine). The present study examined its expression
in the OSS cohort.
Adiponectin is a 30 kD protein that is made almost ex-
clusively by adipose tissue [1], although in culture other
cell types such as hepatocytes can be induced to produce
it [2]. Adiponectin can bind to collagens [3], and is struc-
turally similar to complement component C1q [4]. It cir-
culates in high (lg/mL) concentrations in plasma, appears
to be involved in metabolic disorders such as obesity and
diabetes mellitus, and may enhance insulin sensitivity [4–
6]. Additionally, adiponectin has anti-inflammatory and
vasoprotective properties [4]. For example, adiponectin
blocked tumor necrosis factor a (TNFa)-induced adher-
ence of monocytes to endothelial cells by attenuating
surface expression of the adhesion molecules vascu-
lar cellular adhesion molecule-1 (VCAM-1), intercel-
lular adhesion molecule-1 (ICAM-1), and E-selectin
[7, 8]. Furthermore, adiponectin increased the produc-
tion of tissue inhibitor of metalloproteinase-1 by hu-
man macrophages through an interleukin-10–dependent
mechanism [9]. Adiponectin acts directly on endothelial
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cells to enhance nitric oxide production and, thus, may
function as a vasodilator [10]. Individuals with lower
levels of adiponectin showed impaired endothelium-
dependent vasodilation [11]. Adiponectin was found in
blood vessel walls after experimental endothelial injury
[12], and was strongly expressed around infarcted but not
normal myocardium [3], supporting a role in vascular and
endothelial remodeling.
A small number of studies have examined adiponectin
in patients with kidney disease. Plasma levels are signif-
icantly increased in end-stage kidney disease [13], and
levels declined but did not normalize after successful kid-
ney transplantation [14]. In a small cohort of end-stage
kidney disease patients who underwent abdominal sub-
cutaneous fat biopsy, adiponectin gene expression was
lower than in normal controls [15]. Interestingly, plasma
adiponectin was found to be markedly elevated in pa-
tients with nephrotic syndrome, and this was independent
of glomerular filtration rate [16]. Finally, patients with
overt diabetic nephropathy were observed to have higher
plasma and urine levels of adiponectin than healthy indi-
viduals or diabetics with microalbuminuria [14].
The anti-inflammatory effects of adiponectin, along
with its altered metabolism in patients with kidney dis-
ease, and our finding of apparently high urine levels by
antibody array in patients with active SLE nephritis, pro-
vided the rationale to study adiponectin expression in
SLE.
METHODS
Patients
The subjects of this investigation were enrolled in the
OSS, a prospective, longitudinal study of active patients
with 4 or more American College of Rheumatology cri-
teria for SLE, and have been described previously [17].
Each patient was evaluated clinically and with labora-
tory tests every 2 months, and provided plasma and a
freshly voided urine specimen at each visit. The fresh
urine samples were centrifuged to remove sediment and
supernatants frozen in small aliquots without further ma-
nipulation at −80◦C for later analysis. Plasma samples
were also stored in aliquots at −80◦C.
Adiponectin was measured in plasma and urine from
patients at renal flare. When available, additional urine
specimens collected 4 and 2 months before the renal flare,
and 2 and 4 months after the renal flare were analyzed
from the same patients. For comparison, adiponectin was
also measured in the plasma and urine of healthy volun-
teers, patients with nonrenal flare, and SLE patients with
physician-defined stable renal and nonrenal disease ac-
tivity (disease controls). For disease controls, urine was
obtained from patients who did not have a flare during the
observation period and patients who flared more than 4
months before or after the specimen was collected. Main-
tenance immunosuppression for disease controls was sim-
ilar to the flare group.
Adjudication and classification of SLE activity status
After all clinical results were compiled from each 2-
month study visit, the patient’s study physician deter-
mined whether an SLE flare occurred, whether it was
renal, nonrenal, or both, and whether the flare was mild,
moderate, or severe. Confirmation of the flare was re-
quired by independent review of the data by another
study physician. Identification of flares and determina-
tion of flare severity was based on prespecified criteria
[18–20], as reported previously [17]. Briefly, a mild renal
relapse was defined as an increase in glomerular hema-
turia from <5 to >15 RBC/hpf on urinalysis, with at least
2 acanthocytes/hpf, or recurrence of 1 or more red blood
cell casts or leukocyte casts (in the absence of infection)
or both. A moderate renal relapse was defined as an in-
crease in serum creatinine and/or proteinuria that was
attributable to SLE as follows: if baseline serum creati-
nine was <2 mg/dL, an increase of 0.2 to 1.0 mg/dL; if
baseline creatinine was ≥2, an increase in serum creati-
nine of 0.4 to 1.5 mg/dL. Daily urine protein excretion
rate was estimated by measuring the ratio of protein to
creatinine (Pr/Cr ratio) in a 24-hour urine collection [21].
The proteinuria criteria for moderate relapse were an
increase from a baseline Pr/Cr ratio <0.5 to ≥1; an in-
crease from a baseline Pr/Cr ratio of 0.5 to 1.0 to ≥2; a
doubling of Pr/Cr ratio from a baseline >1.0, with the
absolute ratio <5.0. A severe renal relapse was defined
as an increase in serum creatinine >1.0 mg/dL if baseline
creatinine was <2.0 mg/dL, or an increase in serum crea-
tinine >1.5 mg/dL if baseline creatinine was ≥2.0 mg/dL,
and/or an absolute increase in urine Pr/Cr ratio >5.
A nonrenal flare was declared if the patient devel-
oped symptoms or signs of nonrenal SLE and they were
of sufficient severity that the managing study physi-
cian increased therapy. The severity of nonrenal relapse
was based on the British Isle Lupus Assessment Group
(BILAG) severity categories [20]. A mild nonrenal
relapse was defined as 1 or more of the following
attributable to SLE: typical rash, symmetric mild to
moderate arthralgias, fever, thrombocytopenia 50,000 to
100,000/mm3, significant fatigue, oral ulcers, and mild-
moderate hair loss. A moderate nonrenal relapse was de-
fined as 1 or more of the following: serositis, hemoglobin
9 to 11, thrombocytopenia 25,000 to 50,000/mm3, neu-
trophil count ≤1500/mm3, severe migraine headache,
seizures in the absence of neurologic deficit, uveitis, reti-
nal cytoid bodies, severe alopecia, or extensive mucosal
ulceration. A severe nonrenal relapse was defined as 1 or
more of the following: pulmonary hemorrhage, vasculi-
tis involving abdominal viscera or brain, severe myositis,
thrombocytopenia <25,000/mm3, hemolytic anemia with
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hemoglobin <9, severe rash involving >2/9th body sur-
face area, aseptic meningitis, transverse myelitis, cerebri-
tis, myocarditis, or pericarditis with tamponade.
Immobilized antibody array
Human cytokine antibody array VII was purchased
from RayBiotech (Norcross, GA, USA). Urine samples
(1 mL) were added directly to individual arrays and in-
cubated at room temperature for 2 hours. The arrays
were washed and developed using chemiluminescence
per manufacturer’s directions.
Adiponectin measurement
Plasma and urine adiponectin were measured by spe-
cific enzyme-linked immunosorbent assay (ELISA) ac-
cording to manufacturer’s directions (R&D Systems,
Minneapolis, MN, USA). The lower range of the assay
was 3.9 ng/mL of adiponectin. Urine and plasma values
below this were considered undetectable and assigned a
value of zero. Urine adiponectin levels were standardized
to urine creatinine measured in the same spot urine and
expressed as ng/mg creatinine (ng/mg Cr).
Immunoblotting
Proteins from 15 lL of human urine were directly sep-
arated by polyacrylamide gel electrophoresis under re-
ducing conditions and immunoblotted for adiponectin.
The primary antibody was goat antihuman adiponectin
(AF1065; R&D Systems) used at a concentration of
0.2 lg/mL. To ensure specificity, nonimmune goat IgG
was used in place of the primary antibody for some blots
(not shown). Furthermore, in other experiments 2 lg/mL
recombinant human adiponectin (R&D Systems) was
added to the incubation as a competitor. Blots were devel-
oped using a horseradish peroxidase conjugated-rabbit
anti-goat secondary antibody (Zymed, South San Fran-
cisco, CA, USA) and an enhanced chemiluminescence
system (Amersham, Arlington Heights, IL, USA).
Immunohistochemistry
Paraffin embedded renal biopsies from normal kid-
neys (renal allograft donors), class IV and class V SLE
nephritis patients, or patients with idiopathic membra-
nous glomerulopathy were cut at 2 microns, deparaf-
finized, and subjected to antigen retrieval by heating the
slides to 94◦C in a citric acid solution (pH 6.1) for 25 min-
utes. Endogenous peroxidase and biotin were quenched
and slides were immunostained using a Dako Autostainer
System (Dako, Carpinteria, CA, USA). The primary an-
tibody was goat antihuman adiponectin (R&D Systems),
followed by rabbit antigoat IgG (Vector Laboratories,
Burlingame, CA, USA). The reaction was visualized by
the Vectastain Elite detection system (Vector Laborato-
ries) using diamino benzidine as the chromogen. Slides
were counterstained with hematoxylin I (Richard-Allen
Scientific, Kalamazoo, MI, USA). Specificity of staining
was verified by replacing the primary antibody with a
nonimmune goat primary antibody (not shown, R&D
Systems, #AB-108-C).
Statistics
Data are shown as mean ± SEM. Comparisons be-
tween two groups were done by Student t test. Multi-
ple comparisons were done using multiple regression,
repeated measures analysis of variance (ANOVA), or
Kruskal-Wallace ANOVA as appropriate. Logarithmic
transformation was used when necessary and diagnostics
were carried out for model validation. Specific groups
were compared with post-hoc Tukey HSD or Dunn’s mul-
tiple comparisons test. Associations were tested by simple
and multiple linear regression. P < 0.05 was considered
significant. The statistics program used was SAS JMP ver-
sion 5 (Cary, NC, USA).
RESULTS
In preliminary experiments, urine samples from pa-
tients with renal SLE were screened using an immobi-
lized antibody array for human cytokines. Adiponectin
was consistently found to be present in these urines, and
although this assay is not quantitative, the intensity of
the adiponectin spots generally appeared higher in urine
from patients than healthy individuals (Fig. 1A). To ver-
ify the presence of adiponectin in urine from patients
with SLE, urine samples were directly immunoblotted
with an antibody to human adiponectin (Fig. 1B). This
demonstrated a band around 30 kD, the expected molec-
ular mass of monomeric adiponectin [22]. This band was
attenuated in the presence of excess human recombi-
nant adiponectin, suggesting specificity for adiponectin
(Fig. 1B). Finally, samples of normal kidney tissue (N =
3), class IV SLE nephritis (N = 3), and class V SLE
nephritis (N = 4) were immunostained for adiponectin.
Adiponectin was found on the endothelium and smooth
muscle cells of intrarenal arteries/arterioles, and the
endothelium of glomerular and peritubular capillaries
in normal kidneys (Fig. 2). In idiopathic membranous
nephropathy, adiponectin staining was comparable to
normal kidneys, except for more adiponectin-positive re-
sorption droplets in proximal tubular epithelial cells (not
shown). SLE renal tissue also showed a similar staining
pattern as normal tissue, except in areas of glomeru-
lar hypercellularity or sclerosis and interstitial inflamma-
tion. In these areas endothelial staining was markedly
decreased or absent (Fig. 2). Additionally, podocytes
were focally stained in SLE kidneys (class IV > class V),
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Fig. 1. Identification of adiponectin in urine.
(A) Urine from a healthy individual (Cont),
a patient with active class IV SLE nephritis,
and a patient with active class V SLE nephritis
were incubated on immobilized antibody ar-
rays. The developed arrays demonstrated the
presence of adiponectin (Adip) in the urine
from SLE patients. The blots contained a se-
ries of control wells (Pos Cont) to normalize
spot intensity between individual arrays. (B)
Urine proteins from three SLE patients with
nephritis (class IV or V as indicated) were sep-
arated by electrophoresis and immunoblotted
for adiponectin in the presence or absence of
human recombinant adiponectin (hrAdip). A
specific band was detected around 30 kD.
Fig. 2. Adiponectin in human kidneys. Immunohistochemical staining of human kidney tissue for adiponectin was performed as described in
Methods and representative sections are shown. (A) Normal kidney demonstrates extensive endothelial staining in the glomerular and peritubular
capillaries. (B) A normal glomerulus at higher magnification. (C) An SLE class IV kidney shows similar glomerular and interstitial endothelial
staining except in areas of proliferation or leukocyte infiltration (arrowheads). Adiponectin was also present in podocytes (arrow). (D) An SLE
class IV kidney demonstrates adiponectin in tubular epithelial cells (arrow), and tubular casts (arrowhead).
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Fig. 3. Cohort demographics and plasma
adiponectin levels in healthy individuals and
patients with SLE. (A) Adiponectin was mea-
sured in the plasma of Caucasian (C) and
African American (AA) men and women.
Each symbol represents a single individual
and the bars indicate mean values. The num-
ber of subjects in each group, average age, and
BMI are indicated. ∗P < 0.05 vs. Caucasian
and African American males. (B) Plasma
adiponectin was measured in SLE patients at
renal (R) or nonrenal (NR) flare, and com-
pared to healthy individuals (Cont), and re-
nal (Cont-R) and nonrenal (Cont-NR) dis-
ease controls. For each group the mean age,
BMI, number of African Americans and Cau-
casians (AA/C), and the number of males and
females (M/F) is indicated. ∗P < 0.05 vs. nor-
mal controls and patients at nonrenal flare.
and adiponectin was found in tubular casts and tubular
epithelial cell protein droplets (Fig. 2).
Further investigation of the association of adiponectin
with human SLE was undertaken by measuring plasma
and urine adiponectin in control and patient cohorts.
Figure 3 shows the demographics of the study groups
in this report. Plasma adiponectin levels in healthy in-
dividuals are demonstrated in Figure 3A. After account-
ing for body mass index (BMI), a known determinant
of adiponectin [4], race and gender were found to have
significant effects on plasma levels (P < 0.003 for race
and gender each, using a multiple regression model).
Caucasian females had the highest levels of plasma
adiponectin and were significantly different than Cau-
casian and African American males. There was no statisti-
cal difference between Caucasian and African American
females.
Plasma adiponectin levels and demographics for the
SLE cohort are shown in Figure 3B. Patients with re-
nal SLE flare had a significantly higher mean plasma
adiponectin level than healthy controls and patients with
nonrenal SLE, but not renal disease controls. These
comparisons take into account BMI and race; because
there were so few males in the patient cohort they
were not analyzed separately, and the control group was
composed of healthy African American and Caucasian
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Fig. 4. Plasma adiponectin levels in patients
with inflammatory and non-inflammatory
SLE nephritis. Adiponectin was measured in
the plasma of patients at renal flare, and the
data were segregated on the basis of WHO
biopsy classification at the time of diagnosis.
∗P < 0.02 vs. the noninflammatory group.
females. Interestingly, the mean plasma adiponectin of
the renal flare group combined with the renal disease con-
trol group (19.5 ± 1.8) was significantly higher than the
mean plasma adiponectin from the nonrenal and healthy
control groups combined (10.51 ± 0.7, P < 0.0005).
Multiple regression analysis found no relationship be-
tween plasma adiponectin and serum creatinine or pro-
teinuria at renal flare (P = 0.94). The association with
putative markers of systemic inflammation was also ex-
amined. C-reactive protein (CRP) was negatively corre-
lated with plasma adiponectin at renal flare (r = −0.52,
P < 0.005), whereas erythrocyte sedimentation rate
showed no relationship with plasma adiponectin (P =
0.43).
Patients were separated into inflammatory (class III,
IV) and noninflammatory (class V plus 1 class II patient)
SLE nephritis based on their biopsies at initial diagnosis.
As shown in Figure 4, at renal flare the mean plasma
adiponectin level in the inflammatory group (24.3 ± 3.2
lg/mL, N = 20) was significantly higher than the mean
level in the noninflammatory group (13.8 ± 2.5 lg/mL,
N = 10, P < 0.02). These groups were well matched for
BMI (28.3 ± 1.9 vs. 28.4 ± 1.5) and race (40% vs. 50%
African American). Although not statistically significant,
the urine protein to creatinine ratio tended to be higher
in the noninflammatory group (5.5 ± 1.6 vs. 2.7 ± 0.4, P =
0.12), while serum creatinine tended to be higher in the
inflammatory group (1.49 ± 0.28 vs. 1.01 ± 0.22 mg/dL,
P = 0.09).
Urine adiponectin was below the limit of detection
in all of the healthy controls tested (N = 28, 18 fe-
males, 23 Caucasians, 5 African Americans). In contrast,
adiponectin was present in the urine of patients at renal
flare, and the mean value was significantly greater than
that of patients with nonrenal SLE flare, and renal and
nonrenal disease controls (Fig. 5). Race and BMI did not
affect urine adiponectin.
The relationship of urine adiponectin to urine pro-
tein, serum creatinine, and plasma adiponectin was de-
termined at renal flare. Individual pairwise correlations
demonstrated a significant association between urine
adiponectin and: urine protein (r = 0.45, P < 0.04), serum
creatinine (r = 0.44, P < 0.03), and plasma adiponectin
(r = 0.53, P < 0.006). These 3 variables were used to
construct a predictive model for urine adiponectin by
multiple regression analysis. Taken together, protein-
uria, serum creatinine, and plasma adiponectin were sig-
nificant predictors of urine adiponectin (P < 0.002),
and accounted for 56.4% of the variation in urine
adiponectin. Plasma adiponectin and serum creatinine
were the strongest predictors of urine adiponectin, while
proteinuria contributed only 8% to the model. The renal
disease control cohort showed no significant correlations
between urine and plasma adiponectin, serum creatinine,
or proteinuria.
Serial measurements of plasma and urine adiponectin
were made in 10 patients over the course of 11 renal flares
(Fig. 6). Plasma adiponectin did not change significantly
before, during, or after flare, whereas urine adiponectin
increased markedly at flare, and declined to preflare lev-
els within 4 months of treatment.
The influence of immunosuppressive therapy on urine
and plasma adiponectin was examined. At the time of re-
nal flare most patients had been taking prednisone, my-
cophenolate mofetil, or both. There was no relationship
between urine or plasma adiponectin levels at flare and
the cumulative amount of therapy received in the 30 days
preceding flare (data not shown).
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Fig. 5. Urine adiponectin at renal and non-
renal SLE flare. Adiponectin was measured
in the urine of patients at renal and nonrenal
flare, and in urine from renal and nonrenal
disease controls. ∗P < 0.001 vs. nonrenal flare;
∗P < 0.01 vs. disease controls.
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Fig. 6. Time course of plasma and urine
adiponectin levels in relation to SLE renal
flare. In 11 renal flares plasma and urine
adiponectin were measured in specimens ob-
tained 4 and 2 months before flare and 2
and 4 months after flare. Plasma adiponectin
levels did not change during the flare cycle.
Urine adiponectin at renal flare was signifi-
cantly greater (∗P < 0.05) than either time
point before flare, or at 4 months’ postflare.
DISCUSSION
This work is the first to characterize the expression
of adiponectin in human SLE. While surveying SLE
urine for potential disease biomarkers, a highly abun-
dant cytokine was tentatively identified as adiponectin.
Immunoblotting verified that adiponectin was present in
the urine of those with kidney involvement. Plasma and
urine adiponectin were then measured quantitatively. Af-
ter accounting for BMI, sex, and race, variables known to
influence adiponectin levels [4, 23], we found that plasma
adiponectin was higher in those with renal SLE com-
pared to healthy controls, nonrenal SLE disease controls,
or those with nonrenal SLE flare. Although increased in
renal SLE flare, plasma adiponectin did not change sig-
nificantly before, during, or after treatment of renal SLE
flare. In contrast, urine adiponectin increased dramat-
ically within 2 months of renal flare, but not nonrenal
flare, and declined to preflare levels by the fourth month
postflare. High plasma adiponectin levels and increased
urine adiponectin occurred in renal SLE patients despite
chronic immunosuppression with corticosteroids and, in
many cases, mycophenolate mofetil. Although corticos-
teroids were shown to block adiponectin secretion by cul-
tured adipocytes [24], this was not observed in vivo [14],
and we found no relationship between the amount of im-
munosuppression given and the level of adiponectin ex-
pression. These findings suggest adiponectin expression
is not altered in response to generalized systemic SLE
activity or its therapy, but may specifically reflect kidney
injury during SLE.
The mechanism for the increase in circulating
adiponectin in renal SLE is presently unclear. Previ-
ous studies have shown high plasma adiponectin in pa-
tients with end-stage kidney disease [13, 14]. These data
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were interpreted as evidence for renal clearance or
catabolism of adiponectin under normal circumstances.
However, decreased renal function does not appear to
explain high plasma levels in renal SLE because plasma
adiponectin did not correlate with serum creatinine in pa-
tients with SLE renal flare. Other investigations also did
not find a strong independent effect of GFR on circulating
adiponectin levels in patients with only mild-moderate re-
nal impairment [25, 26]. Alternatively, proteinuria or its
metabolic consequences have been postulated to increase
adiponectin expression. Although a positive association
between proteinuria and circulating adiponectin was ob-
served in nephrotic patients and proteinuric diabetics [16,
27], there was no correlation between plasma adiponectin
and proteinuria at SLE renal flare. Finally, the increase
in circulating adiponectin in SLE does not seem to be a
response to systemic inflammation because there was no
relationship between adiponectin and erythrocyte sedi-
mentation rate, a negative correlation with CRP, and no
increase in levels during nonrenal flare. However, renal
inflammation may influence plasma adiponectin, as sug-
gested by the finding of higher levels in those with inflam-
matory nephritis compared to noninflammatory nephri-
tis. This raises the possibility of communication between
the kidney and adipose tissue.
The increase in urine adiponectin at renal flare ap-
pears to be due, at least in part, to glomerular capillary
leak. This interpretation is supported by the correlation
of urine adiponectin levels with plasma levels and the
magnitude of proteinuria. Additionally, the appearance
of adiponectin in podocytes, tubular cells, and tubular
casts during active nephritis is consistent with this inter-
pretation. The only other report on urine adiponectin
showed that in patients with overt diabetic nephropathy
intact urine adiponectin levels also correlated with pro-
teinuria [27].
Presently it is not clear whether increased urinary ex-
cretion of adiponectin has a functional effect on the
kidney in SLE renal flare, or is simply a biomarker of
SLE activity. Interestingly, in vitro studies have described
several anti-inflammatory activities of adiponectin [3, 4,
7–9, 28, 29], and mice genetically deficient in adiponectin
showed a more severe glomerulonephritis after injection
with antiglomerular basement membrane serum than
wild-type mice [abstract; Li P et al, J Am Soc Nephrol
15:9A, 2004]. It is thus conceivable that adiponectin may
modulate renal inflammation in SLE.
The presence of adiponectin lining glomerular capil-
laries and other endothelial surfaces in the kidney was
an unexpected finding. In rodents, larger blood vessels
did not stain for adiponectin unless the endothelial layer
was disrupted by trauma, after which adiponectin bound
to exposed collagens in the intima [12]. Furthermore, in
normal human myocardium adiponectin was found in the
perivascular interstitium, but was not described in blood
vessels [3]. These observations suggest that kidney en-
dothelium may have unique adiponectin binding prop-
erties, the function of which remains to be explored. It
is also curious that adiponectin staining was absent from
inflamed capillaries. It is possible that the inflammatory
milieu promotes shedding of adiponectin from endothe-
lial surfaces. It is interesting to speculate that this aggra-
vates the local inflammatory cell influx and may account
for the focal nature of tubulointerstitial injury.
CONCLUSION
Urine adiponectin appears to be a fairly sensitive
marker of renal SLE flare. It will be important to pursue
longitudinal testing of urine adiponectin at more frequent
intervals than every 2 months to determine if it increases
early enough in the flare cycle to predict impending clin-
ical relapse. In contrast, elevated plasma adiponectin is
present in patients who have had renal manifestations of
SLE, is not restricted to flare, and appears to be indepen-
dent of renal function and proteinuria. The significance
of high levels of circulating adiponectin in patients with
SLE and kidney involvement remains to be determined.
Testing is currently underway to see if measuring plasma
adiponectin adds to the clinical information of kidney
status obtained from the standard renal biomarkers of
serum creatinine and proteinuria.
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